Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024597 | 0.91 | KDM2B (0.45) | ALDH1A1KMT2AKDM2BL3MBTL1MEN1 | |
| SCHEMBL4027216 | 0.89 | KMT2A (0.41) | ALDH1A1KMT2AGAAKDM2BMEN1 | |
| SCHEMBL4020327 | 0.87 | CPS1 (0.39) | ALDH1A1KMT2AMEN1TP53 | |
| SCHEMBL4025770 | 0.87 | KDM2B (0.41) | ALDH1A1KMT2AKDM2BL3MBTL1MEN1 | |
| SCHEMBL4779468 | 0.86 | ALDH1A1 (0.41) | ALDH1A1KMT2AGAAKDM2BL3MBTL1 | |
| SCHEMBL4026855 | 0.86 | KMT2A (0.44) | ALDH1A1KMT2AGAAKDM2BL3MBTL1 | |
| SCHEMBL4026851 | 0.86 | KMT2A (0.44) | ALDH1A1KMT2AGAAKDM2BL3MBTL1 | |
| SCHEMBL4022832 | 0.85 | KDM2B (0.43) | KMT2AKDM2BL3MBTL1MEN1DRD2 | |
| SCHEMBL4025103 | 0.84 | KDM2B (0.41) | ALDH1A1KMT2AGAAKDM2BL3MBTL1 | |
| SCHEMBL4020633 | 0.83 | MEN1 (0.35) | KMT2AKDM2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | ALDH1A1 258/4885KMT2A 2820/4885GAA 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.